Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...
Kaleido Scope

Intestinal Rehab Program

Intestinal failure is defined as having an intestinal condition which renders a child unable to maintain adequate hydration and meet calorie absorption needs sufficient for growth. This results in ...
Cochrane

What are the benefits and risks of oils given by mouth (enteral lipids) in infants who either have or are at risk of liver disease due to intestinal failure?

There were no studies that specifically studied the effect of enteral lipids in infants at risk of liver disease or who have liver disease due to prolonged need for artificial nutrition secondary to ...
Detroit Free Press

Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and ...
YDR

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal ...

SBS-IF is the second orphan disease target indication for Jaguar’s intestinal failure program, which includes microvillus inclusion disease (MVID) – for which the company completed a meeting in ...
The Indianapolis Star

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...